CGTX

Cognition Therapeutics Inc

Add to Watchlist

Advanced Chart

0.622

-0.048(-7.162%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.6793

Open

0.6701

VWAP

0.63

Vol

2.48M

Mkt Cap

38.57M

Low

0.6008

Amount

1.57M

EV/EBITDA(TTM)

Total Shares

40.06M

22.14M

EV/OCF(TTM)

P/S(TTM)

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

1 Analyst Rating

382.16% Upside

Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

382.16% Upside

Current: 0.622

Low

3.00

Averages

3.00

High

3.00

382.16% Upside

Current: 0.622

Low

3.00

Averages

3.00

High

3.00

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$5 -> $3

2025-05-27

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$5 -> $3

2025-05-27

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Cognition Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm cites the anticipated equity dilution later this year to extend the company's operational runway for the target cut. Zervimesine appears applicable across multiple fronts, the analyst tells investors in a research note.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$6 → $5

2025-03-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$6 → $5

2025-03-24

Maintains

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$11 → $8

2025-03-21

Reason

Chardan Capital

Daniil Gataulin

Price Target

$11 → $8

2025-03-21

Maintains

Strong Buy

Reason

Chardan lowered the firm's price target on Cognition Therapeutics to $8 from $11 and keeps a Buy rating on the shares after the company reported FY24 financial results and provided updates on its programs. Following "promising" data from Phase 2 studies of zervimesine in Alzheimer's disease and dementia with Lewy bodies, Cognition will request end of Phase 2 meetings with the FDA to align on plans for Phase 3, the analyst noted.

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$11

2025-02-26

Reason

Chardan Capital

Daniil Gataulin

Price Target

$11

2025-02-26

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$5 → $6

2024-12-19

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$5 → $6

2024-12-19

Maintains

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$11

2024-12-19

Reason

Chardan Capital

Daniil Gataulin

Price Target

$11

2024-12-19

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cognition Therapeutics Inc (CGTX.O) is -2.05, compared to its 5-year average forward P/E of -2.31. For a more detailed relative valuation and DCF analysis to assess Cognition Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.31

Current PE

-2.05

Overvalued PE

-0.15

Undervalued PE

-4.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

-2.32%

-13.78M

Operating Profit

FY2025Q1

YoY :

-7.33%

-8.48M

Net Income after Tax

FY2025Q1

YoY :

-48.15%

-0.14

EPS - Diluted

FY2025Q1

YoY :

-100.00%

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

30.0K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

500.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

30.0K

USD

Months

0-12

0.0

USD

Months

CGTX News & Events

Events Timeline

2025-07-29 (ET)

2025-07-29

07:38:38

Cognition Therapeutics presents data at AAIC on CT1812 in dementia

2025-07-21 (ET)

2025-07-21

07:34:42

Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study

2025-07-16 (ET)

2025-07-16

07:31:53

Cognition Therapeutics ot present data from zervimesine Phase 2 study

News

9.0

07-29Newsfilter

PinnedCognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

9.0

07-21Newsfilter

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

9.0

07-16Newsfilter

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC